albumin - publications

Predict more albumin - ligand interactions now!

1. J Med Chem. 2012 Apr 23. [Epub ahead of print]

Allosteric Inhibition of Cobalt Binding to Albumin by Fatty Acids: Implications
for the Detection of Myocardial Ischemia.

Lu J, Stewart AJ, Sadler PJ, Pinheiro TJ, Blindauer CA.

The biomarker "Ischemia-Modified Albumin" (IMA), measured by the
albumin-cobalt-binding assay (ACB assay), is the only FDA-approved biomarker for
early diagnosis of myocardial ischemia. Based on the hypothesis that high levels
of free fatty acids are directly responsible for reduction in cobalt binding by
albumin, chemically defined model systems consisting of BSA, Co<sup>2+</sup>, and
myristate were studied by Isothermal Titration Calorimetry, <sup>111</sup>Cd NMR
spectroscopy, and ACB assays. Significantly reduced Co<sup>2+</sup> binding to
albumin, as demonstrated by an increase in absorption of the Co-dithiothreitol
adduct, elicited by adding ca. 3 molar equivalents of myristate was comparable to
that observed in clinical ACB assays. Levels of free fatty acids are elevated
during myocardial ischemia, but also in other conditions that have been
correlated with high IMA values. Hence, IMA may correspond to albumin with
increased levels of bound fatty acids, and all clinical observations can be
rationalised by this molecular mechanism.

PMID: 22519414 [PubMed - as supplied by publisher]